Search Results

Memgen Announces New Clinical Data on MEM-288 in Advanced/Metastatic NSCLC at ASCO 2023 Annual Meeting

Memgen, Inc., a clinical-stage biotechnology company today announced updated clinical data from its first-in-human study of MEM-288, an oncolytic viral therapy, in patients with advanced/metastatic refractory non-small cell lung cancer.

June 6, 2023

·

3 min read

Lone Star Bio

Memgen Reports Results From Its First-In-Human Clinical Trial of MEM-288 in Solid Tumors Refractory to Checkpoint Inhibitors at SITC 2022

Memgen, Inc., a biopharmaceutical company developing potentially life-saving cancer immunotherapies, presented the first clinical data for MEM-288, its oncolytic viral therapy, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA.

November 30, 2022

·

3 min read

Business

Memgen Appoints Kevin M. Coveney as Chief Financial Officer

Memgen, Inc., a clinical-stage biotechnology company developing potentially life-saving cancer immunotherapies, announced that Kevin M. Coveney, CPA, has been appointed Chief Financial Officer.

November 17, 2021

·

2 min read

Policy

Memgen Announces FDA Clearance of IND Application for MEM-288

Memgen, Inc. announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for MEM-288, the company’s wholly-owned cancer immunotherapy candidate for the treatment of multiple solid tumors.

November 3, 2021

·

3 min read

Business

ImmunoCellular Therapeutics And Memgen Announce Letter Of Intent For Potential Joint Immuno-Oncology Collaboration

March 23, 2017

·

6 min read

Drug Development

Memgen Announces Preclinical Results For Its ISF35 Cancer Immunotherapy With Checkpoint Inhibitors In Metastatic Melanoma

November 18, 2015

·

2 min read

Biotech Beach

Memgen Announces Upcoming Presentation for ISF35 in Chronic Lymphocytic Leukemia at 2011 Memgen Annual Meeting

December 9, 2011

·

1 min read

Deals

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Enveric Biosciences announced today the appointment of Kevin Coveney, CPA, to the position of Chief Financial Officer.

February 28, 2023

·

7 min read

Drug Development

Memgen’s ISF35 Sensitizes Leukemia Cells to Chemotherapy

December 8, 2009

·

1 min read

Drug Development

FDA Approves Multiple Investigational New Drug Applications

This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.

November 3, 2021

·

4 min read

·

Alex Keown